This is a guest post by Dr. Andrew K. O’Brien, Ph.
D. Associate Professor of Medicine, Division of Infectious Diseases, and the Director of the Infectious Disease Center, Vanderbilt University Medical Center.
Dr. O ‘Brien has written extensively about his work on cancer and the treatment of other chronic diseases, including obesity, and his research has been cited by some of the world’s leading medical journals.
He has published more than 100 peer-reviewed papers, including two Nobel Prizes, and was a member of the US National Academy of Sciences Scientific Advisory Committee on Cancer.
He is a member, as well, of the Advisory Committee of the National Academy on Health, Medicine, and Society.
For the past 10 years, Dr. K.A.O.B. has been the lead investigator of the Catfish Cancer Treatment Protocol.
He recently presented his findings at the International Meeting of the American Society for the Study of Diabetes and Metabolic Disorders.
He previously presented the Catfire Protocol at the American Diabetes Association (ADA) Annual Meeting in May 2018.
Dr. O O ‘Brien’s Catfish Protocol is the first randomized, controlled trial to evaluate its efficacy against advanced stage tumor in patients with metastatic prostate cancer, with the primary endpoint being survival to hospital discharge.
The Catfish Program is the culmination of more than three years of research by Drs.
O-Brien, D.B., and D.A., the Catfishes program manager.
In the CatFire Protocol, a catfish is injected into a vein of the patient with advanced stage prostate cancer.
The catfish then enters the bloodstream and is removed from the patient by intramuscular injection.
Once in the patient’s bloodstream, the catfish continues to grow and is injected as needed.
This procedure is not a cure, but it does give the patient the best chance of survival.
A study in 2011 showed that a single infusion of the catfishes, which is a very effective and safe way to treat metastatic tumors, resulted in a 24% higher survival rate compared to placebo.
To date, Drs O’Brien and D’A.
have demonstrated that the Catfires Protocol is 100% effective in treating advanced stage metastatic cancer, and they have also demonstrated that their Catfish treatments have significantly lower toxicity than standard chemotherapy, which can be extremely toxic to the body.
Since the CatFISH Program was developed in the early 2000s, the CatFish Program has been able to enroll more than 6,000 patients with advanced prostate cancer who have not responded to standard chemotherapy.
Because the CatFIre Protocol is so effective and has been so successful in treating patients, Dr O’Broin has been invited to participate in a Phase 3 clinical trial to test the CatFuel Protocol.
The CatFuel Trial will enroll up to 10 patients with prostate cancer and will use an in-house Catfish for the treatment.
It is expected that the first patient will be on the Cat Fuel Protocol in a few weeks, and we hope that the initial clinical trial will be completed in September 2019.
The catfish was first developed as a tool to combat cancer in cats.
In a study published in the journal JAMA, the researchers compared the cat’s metabolism and immune system to that of a human cancer patient.
The results showed that the cat had significantly lower cancer-associated IgA, T-cell counts, and platelets.
“The CatFishing Protocol is an elegant and cost-effective way to reduce mortality rates for advanced metastatic cancers,” said Dr. D.D., the clinical lead and co-director of the Center for Catfish and Catfish Therapy at Vanderbilt University.
“I am proud to have the opportunity to be a part of the clinical trial and I look forward to helping lead the development of a CatFisher Protocol for the benefit of patients.”
To learn more about the CatFriendly Protocol, visit CatFriend.com or click here.